SEMINAR ON - PowerPoint Presentation

Slide1

SEMINAR ONDRUG EXCIPIENT COMPATIBILTY STUDY(As a part of preformulation study)

1Slide2

INTRODUCTION2

INCOMPATIBILITY

-Definition

-3 Types

OBJECTIVE OF THE STUDY -Why to screen excipients? 1.need to minimize no of model formulations 2.provide rational basis for selecting excipients 3.Formulation stability studies are time consuming. -Goal of the study( Identify the excipients that) 1.are compatible with API 2.do not have impact on the stability of API -Importance 1.Stabity of formulation can be maximised. 2.Helps to avoid surprise problems. 3.Essential for IND submission. 4.Bridges drug discovery and drug developmentSlide3

COMPATIBILITY TESTS2 Aspects of compatibility tests are

:

1.

Identification of compatible excipients for a formulation. 2. Identification of stable storage conditions2 Types:Solid state reactions: - much slower and difficult to interpret.Liquid state reactions: - easier to detect - Acc. to Stability Guidelines by FDA following conditions should be evaluated for solutions or suspensions 1. Acidic or alkaline pH.

2.

Presence of added substances

3. High oxygen and nitrogen atmospheres. 4. Effect of stress testing conditions.

3Slide4

STEPS IN COMPATIBILITY STUDYThere are THREE steps to consider.1. Sample preparation

2. Storage

3. Method of analysis

4Slide5

SAMPLE PREPARATIONFOR SOLID STATE REACTIONS:

SampleA

: -mixture of drug and excipient

SampleB

: -SampleA+ 5% moistureSampleC: -Drug itself without excipients All the samples of drug-excipient blends are kept for 1-3 weeks at specified storage conditions. Then sample is physically observed . It is then assayed by TLC or HPLC or DSC.Whenever feasible, the degradation product are identified by MASS SPECTROSCOPY, NMR or other relevant analytical techniques.To determine Solid state stability profile of a new compound….To test the Surface Oxidation….. 5Slide6

SAMPLE PREPARATIONFOR LIQUID STATE REACTIONS:

Place the drug in the solution of additives.

Both flint and amber vials are used.

This will provide information about

-Susceptibility to oxidation. -Susceptibility to light exposure. -Susceptibility to heavy metals.In case of oral liquids, compatibility with ethanol, glycerin ,sucrose, preservatives and buffers are usually carried out. 6Slide7

STORAGE CONDITIONThe storage conditions used to examine compatibility can very widely in term of temp. & humidity, but a temp. of 50

°c for storage of compatibility sample is considered appropriate.

Some compounds may require high temp. to make reaction proceed at a rate that can be measured over a convenient time period.

7Slide8

ANALYTICAL TECHNIQUES USED TO DETECT DRUS-EXCIPIENT COMPATIBILITYThermal methods of analysis

DSC- Differential Scanning Calorimetry

DTA- Differential Thermal Analysis

Accelerated Stability Study

FT-IR SpectroscopyDRS-Diffuse Reflectance SpectroscopyChromatographySIC-Self Interactive ChromatographyTLC-Thin Layer ChromatographyHPLC-High Pressure Liquid ChromatographyMiscellaneousRadiolabelled TechniquesVapour Pressure OsmometryFlourescence Spectroscopy8Slide9

DSC- DIFFERENTIAL SCANNING CALORIMETRY DSC is widely used to investigate and predict any physico-chemical interaction between drug and excipients involving thermal changes..

METHOD

-The preformulation screening of drug-excipient interaction requires (1 : 1)Drug:excipient ratio, to maximize the likehood of observing an interaction.

-Mixture should be examined under N

2 to eliminate oxidative and pyrrolytic effects at heating rate ( 2, 5 or 100 c / min) on DSC apparatus.9Slide10

10Slide11

11EXAMPLE: DSC IN OFLOXACIN TABLETS

Trace 1

of figure 1-4 shows peak at 278.330C. (melting endothermic peak of Ofloxacin).

Trace 3

(Physical mixture of Ofloxacin & Lactose) shows absence of peak at 278.330C and slight pre shift in Lactose peaks. DSC RESULT-- INCOMPATIBLE Slide12

12

Trace 5 (Physical mixture of Ofloxacin &

Starch

) shows an early onset at 268.370C. But no other changes in thermogram.

DSC RESULT-- COMPATIBLESlide13

13

Trace 7

(Physical mixture of Ofloxacin &

PVP

) shows no change in position of endothermic peak for PVP but there is increase in peak area and size & shape of peak for Ofloxacin is also decreased. DSC RESULT-- INCOMPATIBLESlide14

14

Trace 9

(Physical mixture of Ofloxacin &

Talc

) shows combine features of each component but there are evident changes in onset. DSC RESULT-- COMPATIBLESlide15

15Slide16

16

DSC STUDY IN ASCORBIC ACID FORMULATION

Excipients: Sod. Crosscarmellose, MCC, Lactose

Thermal stability was performed on ascorbic acid std. samples, binary mix. of ascorbic acid & excipients, under N2 & air atmospheres.

IR & X-Ray Diffractometry: No chemical interactionHowever thermal stability of p’ceutical formulations are different.Temp. of beginning of thermal dregradation for Ascorbic acid is lowered of about 50C for MCC & 100C for Na-crosscarmellose & Lactose.Such facts must be considered for storage planning of tablets. (Ref: C.A. vol:146, No:25, June18,2007,507180t)Slide17

LIMITATIONS OF DSCIf thermal changes are very small, DSC can’t be used.

DSC can not detect the incompatibilities which occur after long term storage.

Eg. MCC / ASPIRIN…

Not applicable if test material exhibits properties that make data interpretation difficult.

ADVANTAGES: -Fast -Reliable and very less sample required.17Slide18

DIFFERENTIAL THERMAL ANALYSIS(DTA)Thermal Analysis is useful in the investigation of solid-state interactions. 

It is also useful in the detection of eutectics. 

Thermograms are generated for pure components and their physical mixtures with other components. 

In the absence of any interaction, the thermograms of mixtures show patterns corresponding to those of the individual components.

  In the event that interaction occurs, this is indicated in the thermogram of a mixture by the appearance of one or more new peaks or the disappearance of one or more peaks corresponding to those of the components.18Slide19

19DTA( DRUG:ENALAPRIL MALEATE)

FORMULATION

RESULT OF DTA

(interaction)

SHELF LIFE

INFERENCE

F

1

(Avicel)

+

3

½

month

Least suitable

F

2

(Spray dried lactose)

––

1 yr and 3 month

Ideal

F

3

(Emcompress)

+

8 month

Not recommended

F

4

(A-tab)

+

9

½

month

Not recommended

(Ref:I.J.P.E.,Jan:2000,153)Slide20

20ACCELARETED STABILITY STUDY

Different formulations of the same drug are prepared.

Samples are kept at 40

º

C / 75 % RH.Chemical stability is assessed by analyzing the drug content at regular interval.Amt. of drug degraded is calculated.% Drug decomposed VS time(month) is plotted.Slide21

DIFFUSE REFLECTANCE SPECTROSCOPYPrinciple:

“Penetration of a portion of incident radiation flux into the interior of the solid sample, return of some portion of radiation to the surface of sample following partial absorption and multiple scattering at boundary of individual sample particles.”

Detects the decomposed products, along with physical and chemical adsorption of excipients on to A.P.I. and vice versa.

Example

: Ethanol mediated interaction between dextroamphatamine sulphate and spray dried lactose in solid–solid mixture:Discoloration of powdered mixture was accelerated by 2 amine and by storage at elevated temp. Two new absorption maxima were observed at 340 nm & 295 nm resply.A + L = A–L  A–HMF21Slide22

DIFFUSE REFLECTANCE SPECTROSCOPYA shift in the diffuse reflectance spectrum

of the drug due to the presence of the excipient indicates

physical adsorption

.

whereas the appearance of a new peak indicates chemisorption or formation of a degradation product. DRS is more useful than HPLC assay to detect surface discoloration due to oxidation or reaction with excipients.22Slide23

SELF INTERACTIVE CHROMATOGRAPHYSIC is useful for proteinous drug and excipients.

METHOD:-

SIC is a modified type of affinity chromatography.

Here,

drug is made immobilized as the SP & soln. to be tested( excipient soln.) acts as MP.Measure Rt (Retention time) & compare with non –retained marker.23Slide24

24PRINCIPLE:-For different mobile phases (i.e. different excipients) the injected drug have different interactions (may be repulsive or attractive) with the SP of drug leads to shift in retention time (

Rt

)

When interaction is repulsive,a sharper peak is obtained at a shorter retention time

When no net interaction between the immobilized drug,Rt=dead volume of column.When attractive interactions,it will have longer retention time& wider peak

FIGURE-1

FIGURE-2

FIGURE-3Slide25

TLC AND HPTLCTLC is generally used as confirmative test of compatibility after performing DSC. S.P. consist of powder (Silica, Alumina, Polyamide, Cellulose & Ion exchange resin) adhered onto glass, plastic or metal plate.

Solution of Drug, Excipient & Drug: Excipient mixture are prepared & spotted on the same baseline at the end of plate.

The plate is then placed upright in a closed chamber containing the solvent which constitutes the M.P.

25Slide26

TLC AND HPTLCAny change in the chromatograph such as the appearance of a new spot or a change in the Rf values of the components is indicative of an interaction.

The technique may be quantitated if deemed necessary.  If significant interaction is noticed at elevated temperatures, corroborative evidence must be obtained by examining mixtures stored at lower temperatures for longer durations. 

Among the advantages of thin-layer chromatography in this application are:

Evidence of degradation is unequivocal.

The spots corresponding to degradation products can be eluted for possible identification. 26Slide27

HPLC AND FLUORESCENT MEASUREMENTHPLC (high pressure liquid chromatography)

Characteristics:

-The APIs and model compounds of diversified chemical structure was studied.

-Elution rate: 7.5 ml/hr at ambient temp.

-Allows the detection and quantification of impurities, which span a wide range of polarities, including nonpolar compounds.FLUORESCENT MEASUREMENT: -This technique is restricted to those compounds, which can generate florescence. As the no. of such compounds are restricted, this method is used in Analysis and not in preformulation 27Slide28

28VAPOR PRESSURE OSMOMETRY & EQUILIBRIUM DIALYSIS

Principle:

‘samples of solutions and pure solvent are introduced into a temperature-controlled enclosure, which is saturated with solvent vapor.Since the vapor pressure of solution is lower than that of solvent, solvent vapor condenses on solution sample causing its temperature to rise. The temperature rise is predicted by Clausis –Clapcyron equation.’

Characteristics:

Either liquid or solid sample and must be soluble in organic solvent or in waterSample must not undego association in solution.Sample size is approx. 3 gms for multiple analysis.Measures a no. of avg. mole. Wt. of about 10,000 Daltons.This method measures interactions, & records the interaction caused by variation of particle no.Slide29

29RADIO LABELLED TECHNIQUES:

It is important when the API is having radio–activity.

Method is carried out by using either 3H or 13C.

Highly sensitive method but the cost of carrying out the method & the availability of well established other techniques & methods, this method is generally not preferred.Slide30

INCOMPATIBLE IMPURITIESChemical impurity profiles

-Very

important in influencing the long term chemical stability

.

Eg:-(1) Evaluation of Hydroperoxides ( HPO) in common pharmaceutical excipients. POVIDONE Contains substantial conc. PEG 400 of HPOs with significant HPC batch to batch or mfger POLYSORBATE 80 to mfger variations.

While

MCC, Lactose, High M.wt PEG, Polyxamer

contains less amt. of HPOs.5% PVP responsible for N-oxide formation of Raloxifen HCl, due to high HPO content. (Ref: J.Ph.Sci,vol:97,Jan:2007,106)30Slide31

31(2)

DCP

– Sometimes, IRON may be present in DCP as impurities. It is incompatible with MECLIZINE HCl . (Fe NMT 0.04%)(3)Gelatin is also containing IRON as impurities, Dark spots may occur in the shell due to the migration of water soluble iron sensitive ingredients from fill material into the shell. Slide32

P- Glycoprotin inhibitor excipientsp-Glycoprotein is

membrane associated transport protein

. It is an efflux pump lies in tissue membranes.

Some excipients have p-Glycoprotein efflux-pump inhibiting properties.

EXAMPLES:- 1.PEG-32 lauric glycerides. 2.Polysorbate-80 3.PEG-50 Stearate 4.Polysorbate-20 5.Polysorbate-85 6.PEG-40 hydrogenated castor oil 7.PEG-35 castor oil (Ref: J.Ph.Sci.,vol:93,Nov:2004,2755)

32Slide33

33Known Incompatibilities

Functional group

Incompatibility

Type of reaction

Primary amine

Mono & Di-saccharides

Amine-Aldehyde &

Amine-Acetal

Ester,

Lactone

Basic component

Ester base hydrolysis, Ring opening,

Aldehyde

Amine, Carbohydrate

Aldehyde-Amine, Schiff base

Or Glycosylamine formation

Carboxyl

Base

Salt formation

Alcohol

Oxygen

Oxidation to Aldehyde

& Ketones

Sulfhydryl

Oxygen

Dimerization

Phenol

Metal

Complexation

Gelatin- Capsule Shell

Cationic Surfactant

DenaturationSlide34

34

Excipient

Incompatibility

Type of reaction

Parabens

Non ionic surfactants

(Polysorbate 80)

Micellization

(Reduced antimicrobial activity)

Plastic Containers

Absorption of

Parabens

Phenylmercuric

Nitrate

Anionic Emulsifying agents, Suspending Agents, Talc, Na-metabisulfite, Na-thiosulfate

Anti-microbial activity

Reduced

Halides

Incompatible

(forms less soluble halogen

compds

)

PEG

Penicillin & Bacitracin

Anti-bacterial activity reduced

Phenol, Tannic acid &

Salicylic acid

Softening &

Liquifaction

Sulphonamide & Dithranol

Discoloration

Film coating

Migration of PEG from tablet film coating, leading to interaction with core componentSlide35

35DECS in solid dosage forms

Example 1

:-

Millard reaction

:- is a non-enzymatic bimolecular browning reaction between reducing sugar and an amine.(Anhydrous lactose: no Millard reaction)Mechanism:-Slide36

36

Example2:-

Effect of Excipients on Hydrate formation in wet masses containing Theophylline

During wet granulation Theophylline Shows Pseudopolymorphic changes that may alter its dissolution rate.In the presence of moisture Theophylline monohydrate is formed which has slow dissolution rate.

Diluents Used:1.α- Lactose monohydrate : Minimum water absorbing capacity. So not able to prevent but enhance Hydrate formation of Theophylline.2.Silicified MCC : Highly water absorbing capacity.Able to inhibit the formation of Theophylline monohydrate at low moisture content.(Ref- J.Ph.Sci,vol:92,Jan:2003,516)Slide37

SILICIFIED MCC –as a multifunctional pharmaceutical excipientMultifunctional excipientCharacteristics offered by Prosolv are high compactibilty, high intrnsic flow, enhanced lubrication efficiency and improved blending properties.

Provide tremendous advantages through out product life cycle.

MCC is a dry binder- when comes in contact with water ,its compressibilty is decreased..but that is not the case with SMCC.

(Ref:CA,Vol:151,No:6, August10,2009 ,131557w)37Slide38

DRUG EXCIPIENT COMPATIBILTY STUDY IN AEROSOLSExample 1:- Interaction of propellent-11 with aqueous drug products.

Propellent 11 is trichloromonofluoromethane.

HCl corrodes the Al-container.

38Slide39

39

Example2:

Beclomethasone- Hydroflouroalkane interactions

:

BDP is a Steroidal drug used in AsthmaManipulation of above interaction: BDP particles coated with amphiphilic macromolecular excipient by Spray drying.Therefore, prevention of aggregation & production of physically stable suspension with excellent aerosolisation properties.(Ref: J. Ph.Sci.,VOL:95,May:2006,1060)Slide40

40Anhydrous ethanol is corrisive to Al containers.

-Hydrogen produced in the reaction increases the pressure of the container.So drugs containing polar solvents tend to be corrosive to bare Al.

For containers which contain 2%Tin and 98% Lead

-Lead reacts with the fatty acids(for product cont.soaps) to form Lead salts which cause valve clogging.Slide41

DRUG EXCIPIENT COMPATIBILTY IN PARENTERAL PRODUCTSAnti-oxidants

Ascorbic acid: Incompatible with acid- unstable drugs

Na bisulfite:+ Epinephrine



Sulphonic acid dvt. -Incompatible in Opthalmic solution containing Phenyl mercuric acetate Edetate salts: Incompatible with Zn Insulin, Thiomerosal, Amphotericin & Hydralazine Preservatives Phenolic Preservatives -Lente- Insulin + Phenolic preservative  Break-down of Bi-sulphide Linkage in Insulin structure.-Protamine- Insulin + Phenolic preservative tetragonal oblong crystals which is responsible for prolong action of insulin.

41Slide42

Surface active agentsPolysorbate 80:

One must concern about the residual peroxide present in Polysorbate.

PS 80



Polyoxyethylene sorbitan ester of Oleic acid ( Unsatd.F.A)PS 20  Polyoxyethylene sorbitan ester of lauric acid ( Satd.F.A)So PS 20 is less prone to oxidation than PS 80. Cosolvants SorbitolIncrease the degradation rate of Penicillin in Neutral and Aqueous solutions. GlycerolIncrease the mobility of freeze-dried formulation leading to peptide deamidation. 42Slide43

43

Sr.

No.

DRUG

EXCIPIENT

INTERACTION

OBSERVED

1.

Nicotinamide &

dimethylisosorbide

Propylene-glycol

Hemolysis (in vivo effect)

2.

Paclitaxel, Diazepam, Propaniddid and Alfaxalone

Cremophor EL (polyoxyl 35 castor oil)

Precipitation of Cremophor EL

COSOLVENTS

Sr.

No.

DRUG

EXCIPIENT

INTERACTION

1.

Lidocaine

Unpurified sesame oil

Degradation of lodocaine

2.

Calcium chloride, phenytion sodium, tetracycline hydrochloride

Soybean oil

Incompatible with

All.

OILS AND LIPIDSSlide44

44

DRUG

EXCIPIENT

INTERACTION

OBSERVED

Proteins

Tween 80 and other nonionic polyether surfactants

Surfactants undergo oxidation and the resultant alkyl hydroperoxides formed contribute to the degradation of protein.

Protein formulations

Thiols such as cystiene, glutawthione asnd thioglycerol

Most effective in stabilizing protein formulations containing peroxide-forming surfactants.

SURFACTANTS & CHELATING AGENTS

Dexamathasone, Estradiol, Iterleukin-2 & Proteins and Peptides

Modified cyclodextrins,

Solubilize and stabilize drugs without apparent compatibility problems.Slide45

45

DRUG

EXCIPIENT

INTERACTION

N-nitrosourea

Tris buffer

Form stable complex with N-nitrosourea and retard the degradation of this agent.

5-flurouracil

Tris buffer

Tris buffer will degrade 5-flurouracil, causing the formation of two degradation products that can cause serious cardiotoxicities

Chlorpromazine

Meta-cresol

Incompatible

Recombinant human interferon gamma

Benzyl alcohol

Benzyl alcohol caused the aggregation of the protein

Cisplatin

Sodium metabisulfite

Sodium metabisulfite inactivates cisplatin

BUFFERS,ANTIMICROBIALS & ANTIOXIDENTS

JPS 2002, Vol. 91, No. 9-12, page 2283-2296.Slide46

REFERENCESPharmaceutical Dosage forms By Leon Lachman & Liberman

Hand book of Pharmaceutical Excipients

Remington’s Pharmaceutical Science,21st edition,2005.

Modern Pharmaceutics by Banker & Rhodes,4th edition,2002.

Theory and Practice of Industrial Pharmacy by Lachman & Lieberman.Int. J. Ph.Exci., Vol-1, Jan-2000, 153.Int. J. Ph.Exci., Nov-2002, 2283Int. J. Ph.Exci.,jan-march,2003J. Ph. Sci..,Vol-97, Jan-2007,106J. Ph. Sci., Vol-95, May-2006, 976.J. Ph. Sci., Vol-95, May-2006, 1060.J. Ph. Sci., Vol-95, June-2006, 1342.J. Ph. Sci., Vol-93, Jan-2004,132 J. Ph. Sci., Vol-93, Nov-2004, 2755.J. Ph. Sci., Vol-92, May-2003, 516.JPS 2002, Vol. 91, No. 9-12, page 2283-2296C.A. vol:146, No:25,June 18 :2007,507180t

C.A. vol:147, No:4, July 23 :2007,79121

CA,Vol:151,No:6, August10,2009 ,131557w

46